Sign in Subscribe
Chronic kidney failure

Ultrasensitive Chemiluminescent Probe Developed for Acute Kidney Injury Diagnosis

Strategic Insights

— 1 min read

Acute kidney injury (AKI) poses a significant threat to global health due to its association with chronic kidney disease (CKD) and substantial morbidity and mortality. Current diagnostic techniques, relying on serum creatinine (sCr) and blood urea nitrogen (BUN), are insufficiently sensitive to detect early tubular damage. A team of researchers from Southern Medical University has addressed this challenge by creating a novel chemiluminescent probe called NAG-CL. This innovative tool has demonstrated exceptional performance in detecting AKI, offering rapid activation, an ultra-low detection limit, and high selectivity.

Key Takeaways:

  • The NAG-CL probe is activated by N-acetyl-beta-D-glucosaminidase (NAG), a biomarker that rises in the early stages of AKI.
  • In vitro studies confirmed the specificity and sensitivity of NAG-CL, surpassing traditional fluorescent probes by 16.4 times in terms of lower limit of detection (LOD).
  • Non-invasive urine tests in mice with cisplatin-induced AKI showed early detection of NAG, which correlated with the progression of renal injury.
  • NAG-CL holds promise as a fast and effective non-invasive diagnostic tool for AKI in clinical settings.
  • This research has been peer-reviewed and published in the journal Bioorganic Chemistry.
  • The probe's unique features make it a potential game-changer in the diagnosis of AKI, offering superior performance compared to existing methods.

Statistics:

  • The NAG-CL probe has an ultra-low detection limit of 0.004 U/L.
  • The probe's rapid activation occurs in less than 20 minutes.
  • In vitro studies demonstrated a 16.4 times lower limit of detection (LOD) compared to traditional fluorescent probes.
  • Non-invasive urine tests in mice showed early detection of NAG, correlated with the progression of renal injury.

Sources:

  • Ultrasensitive Chemiluminescent Probe Activated By Nag for Real-time Monitoring of Aki. Bioorganic Chemistry, 2025;164.
  • Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA.
  • Kui Cheng, Southern Medical University, School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Nmpa Key Lab Res & Evaluat Drug Metab, Hong Kong 510515, People's Republic of China.
  • Liyi Tan, En Liang, Xinhui Zheng, Xiayu Feng, Hanying Ding, Xiaobing Yang, and Ting Chen, co-authors on the research.

Read more